Abstract | Objectives: Methods: Results: One-hundred-seventeen (32.3%) patients and 39 (23.6%) HC were affected by SARS-CoV-2 infection. Forty (34.2%) patients experienced an IA flare within one month of infection, of whom 3 (7.5%) needed to switch therapy. The prevalence of SARS-CoV-2 infection, disease severity, and hospitalization rate were not significantly different. At least one shot of SARS-CoV-2 vaccine was administered in 331 (91.4%) patients and 147 (89.1%) HC. Within 48 hours, 102 (30.8%) patients developed vaccine-related AEs; 52 (15.7%) patients with >1 vaccine dose experienced an IA flare-up, of whom 12 (23.1%) needed to switch therapy. Conclusions: A significantly higher rate of IA flare was observed among patients who contracted SARS-CoV-2 infection vs. those without infection. Patients with IA experienced flares after SARS-CoV-2 vaccination, though it was not statistically significant.
|
Authors | Giovanni Striani, Ariela Hoxha, Mariagrazia Lorenzin, Giacomo Cozzi, Laura Scagnellato, Tatiana Vangelista, Francesca Frizzera, Pierino De Sandre, Paolo Simioni, Andrea Doria, Roberta Ramonda |
Journal | Frontiers in immunology
(Front Immunol)
Vol. 14
Pg. 1207015
( 2023)
ISSN: 1664-3224 [Electronic] Switzerland |
PMID | 37564642
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Striani, Hoxha, Lorenzin, Cozzi, Scagnellato, Vangelista, Frizzera, De Sandre, Simioni, Doria and Ramonda. |